CiteFacts · FDA Drug Shortages · FDA source
Methylphenidate Hydrochloride Tablet, Extended Release
Status
FDA currently lists this ingredient in shortage.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Presentation | FDA availability field | FDA update |
|---|---|---|---|
| Janssen Pharmaceuticals | Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01) | Available | 08/19/2026 |
| Janssen Pharmaceuticals | Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01) | Available | 08/19/2026 |
| Janssen Pharmaceuticals | Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01) | Available | 08/19/2026 |
| Janssen Pharmaceuticals | Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01) | Available | 08/19/2026 |
| Lannett Company, Inc. | Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37) | Available | 08/18/2026 |
| Lannett Company, Inc. | Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37) | Available | 08/18/2026 |
| Lannett Company, Inc. | Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37) | Available | 08/18/2026 |
| Lannett Company, Inc. | Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37) | Available | 08/18/2026 |
| Sun Pharmaceutical Industries, Inc. | Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88) | Unavailable | 08/05/2026 |
| Sun Pharmaceutical Industries, Inc. | Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88) | Unavailable | 08/05/2026 |
| Sun Pharmaceutical Industries, Inc. | Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88) | Unavailable | 08/05/2026 |
| Sun Pharmaceutical Industries, Inc. | Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88) | Unavailable | 08/05/2026 |
| Teva Pharmaceuticals USA, Inc. | Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01) | Limited Availability | 08/17/2026 |
| Teva Pharmaceuticals USA, Inc. | Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01) | Available | 08/17/2026 |
| Teva Pharmaceuticals USA, Inc. | Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01) | Limited Availability | 08/17/2026 |
| Teva Pharmaceuticals USA, Inc. | Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01) | Limited Availability | 08/17/2026 |
| Trigen Laboratories, LLC | Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10) | Limited Availability | 08/17/2026 |
| Trigen Laboratories, LLC | Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10) | Limited Availability | 08/17/2026 |
| Trigen Laboratories, LLC | Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10) | Limited Availability | 08/17/2026 |
| Trigen Laboratories, LLC | Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30) | Limited Availability | 08/17/2026 |
| Trigen Laboratories, LLC | Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10) | Limited Availability | 08/17/2026 |
| Trigen Laboratories, LLC | Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30) | Limited Availability | 08/17/2026 |
| Trigen Laboratories, LLC | Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30) | Limited Availability | 08/17/2026 |
| Vertical Pharmaceuticals, LLC | Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10) | Available | 08/17/2026 |
| Vertical Pharmaceuticals, LLC | Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30) | Available | 08/17/2026 |
| Vertical Pharmaceuticals, LLC | Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10) | Available | 08/17/2026 |
| Vertical Pharmaceuticals, LLC | Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30) | Available | 08/17/2026 |
| Vertical Pharmaceuticals, LLC | Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10) | Available | 08/17/2026 |
| Vertical Pharmaceuticals, LLC | Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30) | Available | 08/17/2026 |
| Vertical Pharmaceuticals, LLC | Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30) | Available | 08/17/2026 |
| Vertical Pharmaceuticals, LLC | Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10) | Available | 08/17/2026 |
| Vertical Pharmaceuticals, LLC | Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30) | Available | 08/17/2026 |
| Vertical Pharmaceuticals, LLC | Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30) | Available | 08/17/2026 |
| Vertical Pharmaceuticals, LLC | Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30) | Available | 08/17/2026 |
Source facts
Grouped generic ingredient: Methylphenidate Hydrochloride Tablet, Extended Release · 34 package records · Latest FDA row update: 08/19/2026
Therapeutic categories: Psychiatry
Dosage forms: Tablet
Routes: ORAL
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-08-22T15:54:11+00:00. Derived grouping is documented in this record's derivations.